.jpeg?token=b3f7843d82b66067e2db74c657515cfc)
Toma Biosciences
.png?token=1b8994891672fbc32acecad5f4f057d2)
Diagnostics and laboratory services
TOMA Biosciences develops reagent kits that enable laboratories and researchers to uncover genomic changes in tumors. The company offers TOMA OS-Seq, an oncology-focused gene analysis solution. It serves laboratories, hospital systems, and research institutions worldwide.
Since the investment, Toma Biosciences has merged with Trident Laboratories Inc., a provider of laboratory services. The value of Cantilever’s position in the merged company represents an increase of 18% over the initial investment. The initial Cantilever investment in TOMA was converted to Trident common shares in the merger.